Literature DB >> 33395598

Neuregulin-1 converts reactive astrocytes toward oligodendrocyte lineage cells via upregulating the PI3K-AKT-mTOR pathway to repair spinal cord injury.

Zhenfei Ding1, Ce Dai1, Lin Zhong1, Rui Liu1, Weilu Gao1, Hui Zhang1, Zongsheng Yin2.   

Abstract

Axonal demyelination is a consistent pathological characteristic of Spinal cord injury (SCI). Promoting differentiation of oligodendrocytes is of importance for remyelination. Conversion of reactive astrocytes with stem cell potential to oligodendrocytes is proposed as an innovative strategy for SCI repair. Neuregulin-1 (Nrg1) plays an essential role in the differentiation of oligodendrocytes. Therefore, it's a potential treatment for demyelination in SCI that using Nrg1 to drive reactive astrocytes toward oligodendrocyte lineage cells. In this study, tumor necrosis factor-α (TNF-α) was used to induce dedifferentiation of primary rat spinal cord astrocytes into reactive astrocytes and Nrg1 was used to induce astrocytes in vitro and in vivo. The results showed that astrocytes treated with TNF-α expressed immaturity markers CD44 and Musashi1 at mRNA and protein levels, indicating that TNF-α induced the stem cell state of astrocytes. Nrg1 induced reactive astrocytes to express oligodendrocyte markers PDGFR-α and O4 at mRNA and protein levels, indicating that Nrg1 directly converts reactive astrocytes toward oligodendrocyte lineage cells. Moreover, upregulation of PI3K-AKT-mTOR signaling activation in response to Nrg1 was observed. In rats with SCI, intrathecal treatment with Nrg1 converted reactive astrocytes to oligodendrocyte lineage cells, inhibited astrogliosis, promoted remyelination, protected axons and eventually improved BBB score. All the biological effects of Nrg1 were significantly reversed by the co-administration of Nrg1 and ErbB inhibitor, suggesting that Nrg1 functioned through the receptor ErbB. Our findings indicate that Nrg1 is sufficient to trans-differentiate reactive astrocytes to oligodendrocytes via the PI3K-AKT-mTOR signaling pathway and repair SCI. Delivery of Nrg1 for the remyelination processes could be a promising strategy for spinal cord repair.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Neuregulin-1; Oligodendrocyte; Reactive astrocyte; Remyelination; Spinal cord injury

Mesh:

Substances:

Year:  2021        PMID: 33395598     DOI: 10.1016/j.biopha.2020.111168

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  A Glance at the Molecules That Regulate Oligodendrocyte Myelination.

Authors:  Shunqi Wang; Yingxing Wang; Suqi Zou
Journal:  Curr Issues Mol Biol       Date:  2022-05-15       Impact factor: 2.976

Review 2.  Cellular Reprogramming and Its Potential Application in Alzheimer's Disease.

Authors:  Chao Zhou; Wanyan Ni; Taiyang Zhu; Shuyu Dong; Ping Sun; Fang Hua
Journal:  Front Neurosci       Date:  2022-04-07       Impact factor: 5.152

3.  EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes.

Authors:  Xinyu Liu; Conghui Li; Jiao Li; Lesi Xie; Zeng Hong; Kang Zheng; Xiaofeng Zhao; Aifen Yang; Xiaofeng Xu; Huaping Tao; Mengsheng Qiu; Junlin Yang
Journal:  Mol Med       Date:  2022-05-04       Impact factor: 6.376

4.  Deciphering Pharmacological Mechanism of Buyang Huanwu Decoction for Spinal Cord Injury by Network Pharmacology Approach.

Authors:  Zhencheng Xiong; Feng Yang; Wenhao Li; Xiangsheng Tang; Haoni Ma; Ping Yi
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-22       Impact factor: 2.629

Review 5.  Neuregulin-1, a potential therapeutic target for cardiac repair.

Authors:  Yan Wang; Jianliang Wei; Peng Zhang; Xin Zhang; Yifei Wang; Wenjing Chen; Yanan Zhao; Xiangning Cui
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

Review 6.  Thyroid hormone-dependent oligodendroglial cell lineage genomic and non-genomic signaling through integrin receptors.

Authors:  Rahimeh Emamnejad; Mary Dass; Michael Mahlis; Salome Bozkurt; Sining Ye; Maurice Pagnin; Paschalis Theotokis; Nikolaos Grigoriadis; Steven Petratos
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.